SWM
CRVS icon

Shelton Wealth Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Shelton Wealth Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,268
Closed -$179K – 150
2026
Q1 		$179K Sell
12,268
-3,370
-22% -$53.8K 0.08% 122
2025
Q4 		$120K Buy
15,638
+1,896
+14% +$15K 0.05% 142
2025
Q3 		$101K Buy
+13,742
New +$70.3K 0.05% 138

Other funds holding CRVS

TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
AIM
Avity Investment Management Greenwich, Connecticut $1.57B AUM 35.56% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Shelton Wealth Management's CRVS Position: Q2 2026 in Review

Shelton Wealth Management sold out of Corvus Pharmaceuticals (CRVS) in Q2 2026, closing a stake of 12,268 shares — an estimated $179K sold.

Shelton Wealth Management first reported a position in CRVS in Q3 2025 and held it in 3 quarters. The position peaked at $179K in Q1 2026. 8 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Shelton Wealth Management reported no remaining Corvus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Shelton Wealth Management sold 12,268 Corvus Pharmaceuticals shares in Q2 2026, an estimated $179K.
  • Shelton Wealth Management first reported a position in Corvus Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Shelton Wealth Management's Corvus Pharmaceuticals position peaked at $179K in Q1 2026.
  • 8 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Shelton Wealth Management's 13F filing for Q2 2026, filed 13 Jul 2026.